Nevro Corp (NYSE:NVRO) VP Doug Alleavitch sold 1,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $100.00, for a total value of $100,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
NVRO stock traded up $2.21 on Friday, hitting $105.59. 798,622 shares of the company’s stock were exchanged, compared to its average volume of 519,500. Nevro Corp has a 12-month low of $34.75 and a 12-month high of $108.20. The firm has a 50 day moving average price of $85.16 and a two-hundred day moving average price of $72.40. The company has a debt-to-equity ratio of 0.89, a quick ratio of 4.66 and a current ratio of 6.05. The stock has a market cap of $2.69 billion, a P/E ratio of -64.38 and a beta of 0.21.
Nevro (NYSE:NVRO) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.27. Nevro had a negative return on equity of 41.07% and a negative net margin of 24.51%. The firm had revenue of $100.16 million for the quarter, compared to the consensus estimate of $92.27 million. During the same period in the previous year, the business earned ($0.37) EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Sell-side analysts expect that Nevro Corp will post -3.99 earnings per share for the current fiscal year.
Several research analysts have recently commented on NVRO shares. Zacks Investment Research raised Nevro from a “sell” rating to a “hold” rating and set a $67.00 price target for the company in a research report on Tuesday, August 13th. Leerink Swann set a $98.00 price target on Nevro and gave the stock a “buy” rating in a research report on Friday, August 23rd. Morgan Stanley boosted their target price on Nevro from $76.00 to $100.00 and gave the stock an “overweight” rating in a research note on Thursday. ValuEngine downgraded Nevro from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Canaccord Genuity boosted their target price on Nevro from $59.00 to $88.00 and gave the stock a “hold” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $83.33.
A number of institutional investors have recently bought and sold shares of NVRO. Quest Capital Management Inc. ADV purchased a new stake in Nevro during the 3rd quarter valued at about $26,000. Quantamental Technologies LLC purchased a new stake in Nevro during the 2nd quarter valued at about $75,000. Prudential Financial Inc. purchased a new stake in Nevro during the 2nd quarter valued at about $202,000. Creative Planning purchased a new stake in Nevro during the 3rd quarter valued at about $224,000. Finally, Aperio Group LLC purchased a new stake in Nevro during the 2nd quarter valued at about $227,000.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Recommended Story: How to invest using market indexes
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.